Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021).

Abstract excerpt

INTRODUCTION: KRAS is one of the most important oncology proteins, which can activate multiple downstream signaling pathways. Despite the prevalence of KRAS mutations in approximately 30% of human cancers, it has long been considered to be 'undruggable' due to the lack of recognizable binding pockets. AREAS COVERED: This review covers the recent patents (2019-2021) on KRASG12C inhibitors, which are mostly...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Neoplasms
• Share to Mutation
• Share to Patents as Topic